How the DEA and FDA will regulate psychedelic medicine

from Business Trip · host Greg Kubin & Matias Serebrinsky

In this week’s episode, we chat with Matt Zorn, an attorney at Yetter Coleman with expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA’s decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker’s psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley’s DEA case related to cannabis scheduling. Matt also writes the drug policy newsletter On Drugs.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Episode metadata supplied by the publisher feed · Published Jun 24, 2022

Embed this episode

Attribution link and audio player

Ready to play

How the DEA and FDA will regulate psychedelic medicine

0:00 48:51

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Business Trip?

This episode is 48 minutes long.

When was this Business Trip episode published?

This episode was published on June 24, 2022.

Can I download this Business Trip episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!